Literature DB >> 27349195

Haematological cancer: Cytarabine - new standard of care for MCL.

Diana Romero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27349195     DOI： 10.1038/nrclinonc.2016.104

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Authors:  Olivier Hermine; Eva Hoster; Jan Walewski; André Bosly; Stephan Stilgenbauer; Catherine Thieblemont; Michal Szymczyk; Reda Bouabdallah; Michael Kneba; Michael Hallek; Gilles Salles; Pierre Feugier; Vincent Ribrag; Josef Birkmann; Roswitha Forstpointner; Corinne Haioun; Mathias Hänel; René Olivier Casasnovas; Jürgen Finke; Norma Peter; Kamal Bouabdallah; Catherine Sebban; Thomas Fischer; Ulrich Dührsen; Bernd Metzner; Georg Maschmeyer; Lothar Kanz; Christian Schmidt; Richard Delarue; Nicole Brousse; Wolfram Klapper; Elizabeth Macintyre; Marie-Hélène Delfau-Larue; Christiane Pott; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling
Journal:  Lancet       Date:  2016-06-14       Impact factor: 79.321
  1 in total
  2 in total

1.  RNA Targeting in Acute Myeloid Leukemia.

Authors:  Alessandra Messikommer; Katja Seipel; Stephen Byrne; Peter J M Valk; Thomas Pabst; Nathan W Luedtke
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-12

2.  Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.

Authors:  Therese Triemer; Alessandra Messikommer; Stella M K Glasauer; Jawad Alzeer; Miriam H Paulisch; Nathan W Luedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.